ロード中...
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/B...
保存先:
| 出版年: | NPJ Breast Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Nature Publishing Group UK
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7985189/ https://ncbi.nlm.nih.gov/pubmed/33753748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00240-w |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|